Bidding war for Salix shows confidence in its lead drug

The bidding war for Raleigh's Salix Pharmaceuticals (Nasdaq: SLXP) shows that Valeant (NYSE: VRX) has high confidence that Salix will receive a secondary approval for its biggest selling drug Xifaxan. Specifically, Salix applied with the U.S. Food and Drug Administration to sell Xifaxan as a treatment for irritable bowel syndrome with diarrhea, or IBS-D, something analysts predict will significantly increase revenue. Indeed, it is this indication for this drug that has made Salix become such an…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news